Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant

Cancer Immunology, Immunotherapy

Volumn 49, Issue 11, 2001, Pages 603-612

  Hilburger Ryan, M ^a   Abrams, S I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CTL; Mouse; Peptides; Tumor immunity

Indexed keywords

CD8 ANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN P53; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL INTERACTION; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FIBROSARCOMA; GENE MUTATION; GENE OVEREXPRESSION; LUNG METASTASIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE;

EID: 2042495412     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620000156     Document Type: Article

References (24)

1. Rational antigen modification as a strategy to upregulate or downregulate antigen recognition
2. 65-73 wild type peptide loaded on dendritic cells in vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein
3. Approaches to improve engineered vaccines for human immunodeficiency virus and other viruses that cause chronic infections
4. Molecular themes in oncogenesis
5. + CTL peptide epitope variant that possesses enhanced MHC class I binding and immunogenic properties
6. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells
7. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck
8. Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
9. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
10. A sharper Bonferroni procedure for multiple tests of significance
11. p53 mutations in human cancers
12. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53
13. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specitic T cell response from a type 2 to a type 1 cytokinc profile
14. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy
15. A wild-type p53 cytotoxic T cell epitope is presented by mouse hepatocarcinoma cells
16. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines
17. + T cells
18. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin-2
19. Principles for adoptive T cell therapy of human viral diseases
20. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide
21. Exact prediction of a natural T cell epitope
22. Comparison of linear and branched peptide forms (MAPS) in the induction of T helper responses to point-mutated ras immunogens
23. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
24. In vivo primary induction of virus-specific CTL by immunization with 9-mer synthetic peptides